Melanoma/Skin Cancer News

Smoking status added to the National Cancer Database for patients diagnosed with cancer in 2023 revealed variations in sociodemographic and socioeconomic factors, according to a research letter in JAMA Oncology.

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their confirmatory trials demonstrated meaningful clinical benefits, according to results of a retrospective study.

Cancer mortality gradually declined over the past 2-plus decades, although the rate slowed between 2019 and 2022, according to results of the Annual Report to the Nation on the Status of Cancer.

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance intended to improve the design of randomized phase 3 trials.

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly one-quarter of cases, according to a research letter published in JAMA Dermatology.

The FDA announced it will be reducing, refining and potentially replacing the animal testing requirement for the approval of certain drugs, which could have implications for the approval of new sunscreen ingredients in the United States.

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early study results.

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.

A text message-based electronic triage system showed efficacy for collecting patient-reported treatment outcomes and minimizing the time burden of cancer care, according to results of a pilot study.